Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Breast Neoplasms 7Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Large-Cell, Anaplastic 3Lymphoma 3Immunoblastic Lymphadenopathy 3Esophageal Neoplasms 3Central Nervous System Neoplasms 3Burkitt Lymphoma 3Adenocarcinoma Of Esophagus 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Rectal Neoplasms 2Precancerous Conditions 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Multiple Myeloma 2Lymphoma, T-Cell, Peripheral 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Liver Neoplasms 2Leukemia 2Gliosarcoma 2Glioblastoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2

Interventions

Cisplatin 16Cetuximab 16Radiotherapy, Intensity-Modulated 10Radiotherapy 7Docetaxel 7Fluorouracil 5Erlotinib Hydrochloride 5Everolimus 4Carboplatin 4Sorafenib 3Paclitaxel 3Fluorodeoxyglucose F18 3Chemotherapy, Adjuvant 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3Ultrasonography 2Taxes 2Sirolimus 2Radiotherapy, Conformal 2Radiation 2Platinum 2Photochemotherapy 2Magnetic Resonance Spectroscopy 2Cryosurgery 2Celecoxib 2Biopsy 2Bevacizumab 21-phenyl-3,3-dimethyltriazene 21,2-diaminocyclohexaneplatinum II citrate 2temsirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Tongue Neoplasms × Microarray Analysis × Clear all
NCT01332279 2023-04-04

Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy

Fox Chase Cancer Center

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡